UPCI Melanoma Researchers Present Findings at Annual Meeting of American Society of Clinical Oncology
CHICAGO, June 5 – Researchers from the University of Pittsburgh Cancer Institute (UPCI) Melanoma Program, led by John M. Kirkwood, M.D., will present findings from seven studies at the American Society of Clinical Oncology annual meeting, June 4 to 8, at McCormick Place in Chicago.
Highlights of their findings include:
Phase II Trial of Dasatinib in Patients with Advanced Melanoma
Sponsored by ECOG
Pre-clinical studies show that a specific gene mutation may increase chemotherapy resistance in certain melanoma patients. This study reports the developing approach of a new targeted therapy aimed at a mutation of the gene known as CKIT, which is associated with melanomas of the palms of the hands and soles of the feet where solar radiation does not play a recognized role. It is hoped that this trial, which tests a new molecular inhibitor (dasatinib) of mutated CKIT, will cause antitumor effects in melanomas with this gene mutation. Abstract TPS312
# # #
About University of Pittsburgh Cancer Institute (UPCI)
As the only NCI-designated comprehensive cancer center in western Pennsylvania, UPCI is a recognized leader in providing innovative cancer prevention, detection, diagnosis, and treatment; bio-medical research; compassionate patient care and support; and community-based outreach services. UPCI investigators are world-renowned for their work in clinical and basic cancer research.
http://www.upmc.com/mediarelations
CONTACT: Courtney McCrimmon, McCrimmonCP@upmc.edu
PHONE: (412) 715-8894
CONTACT: Wendy Zellner, ZellnerWL@upmc.edu
PHONE: (412) 586-9777
Tags: